Resistance mechanisms against osimertinib in lung adenocarcinoma cells with EGFR-activating mutation

被引：0
|
作者：
Nishihara, Shigetoshi [1 ,2 ]
Yamaoka, Toshimitsu [1 ,3 ]
Hasebe, Yuki [1 ]
Ishikawa, Fumihiro [4 ]
Kusumoto, Sojiro [3 ]
Ohmori, Tohru [3 ]
Sagara, Hironori [3 ]
Yoshida, Hitoshi [2 ]
Tsurutani, Junjii [1 ]
机构：
[1] Showa Univ, Adv Canc Trans Res Inst, Tokyo, Japan
[2] Showa Univ, Div Gastroenterol, Dept Med, Med Sch, Tokyo, Japan
[3] Showa Univ, Div Allergol & Respi Med, Dept Med, Med Sch, Tokyo, Japan
[4] Showa Univ, Ctr Biotechnol, Tokyo, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2365
引用
收藏
页码：1494 / 1494
页数：1
相关论文
共 50 条
  • [21] Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation
    Chiang, Chi-Lu
    Yeh, Yi-Chen
    Chou, Teh-Ying
    Chiu, Chao-Hua
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (09) : 1439 - 1441
  • [22] Dual Inhibition of EGFR and BRAF Can Be Harmful in Patients Harboring an EGFR-Activating Mutation
    Oh, Sekyung
    Lim, Jun Hyeok
    Park, Nuri
    Choi, Seohee
    Ryu, Jeong-Seon
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : E32 - E34
  • [23] Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib
    Schmid, Sabine
    Stewart, Erin L.
    Martins-Filho, Sebastiao N.
    Cabanero, Michael
    Wang, Ao
    Bao, Hua
    Wu, Xue
    Patel, Deval
    Chen, Zhuo
    Law, Jennifer H.
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Leighl, Natasha
    Tsao, Ming-Sound
    Pugh, Trevor
    Bratman, Scott, V
    Sacher, Adrian
    Liu, Geoffrey
    CLINICAL LUNG CANCER, 2020, 21 (05) : E488 - E492
  • [24] B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression
    Lu, Youwei
    Wu, Fengying
    Cao, Qiuyi
    Sun, Yu
    Huang, Moli
    Xiao, Jing
    Zhou, Bin
    Zhang, Liang
    ONCOGENE, 2022, 41 (05) : 704 - 717
  • [25] Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma
    Kaira, Kyoichi
    Imai, Hisao
    Kagamu, Hiroshi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 1177 - 1182
  • [26] Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
    Wang, Yu
    Liu, Songtao
    Feng, Alei
    Luo, Huan
    Hu, Jinwei
    Wang, Kai
    Dong, Wei
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [27] Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790M mutation
    Zheng, Lin-Peng
    Chen, Li-Ying
    Liao, Xing-Yun
    Xu, Zi-Han
    Chen, Zheng-Tang
    Sun, Jian-Guo
    BMC CANCER, 2018, 18
  • [28] Novel LZTR1 germline mutation as a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma: a case report
    Park, Wai
    Fricke, Jeremy
    Mambetsariev, Isa
    Velasquez, Giovanny
    Nadaf-Rahrov, Reza
    Dingal, Shaira Therese
    Kim, Pauline
    Babikian, Razmig
    Amini, Arya
    Afkhami, Michelle
    Salgia, Ravi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02) : 625 - 630
  • [29] Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
    Lin-Peng Zheng
    Li-Ying Chen
    Xing-Yun Liao
    Zi-Han Xu
    Zheng-Tang Chen
    Jian-Guo Sun
    BMC Cancer, 18
  • [30] Possible new mechanisms of primary drug resistance in NSCLC with EGFR mutation treated with Osimertinib
    Shao, Lujing
    Li, Tong
    Jia, Xinyan
    Zhang, Xinyu
    Li, Qi
    Dong, Chunyan
    IUBMB LIFE, 2025, 77 (02)
12345